Vision Serentiy are looking for Volunteers to join their Sickle Cell Study Research Programme of VIT-2763 – a new potential treatment under development for the symptoms of Sickle Cell Disease
The purpose of this study is to explore the safety, tolerability and effectiveness of a study drug called VIT-2763 for sickle cell disease (SCD). Specifically, we want to investigate its effects on the breakdown of red blood cells and inflammation associated with sickle cell disease.
VIT-2763 targets and blocks a protein in the body called ferroportin. Ferroportin allows the body to transport iron to the blood stream. Iron is important in the production of haemoglobin, the protein that transports oxygen in red blood cells. It is expected that, by blocking ferroportin, VIT-2763 may lower the iron level in the blood. This might reduce the concentration of abnormal haemoglobin (sickle cells) in the red blood cells, and it may reduce the destruction of red blood cells caused by SCD.
VIT-2763 is being developed by Vifor International Inc., the sponsor of this study. It has been tested before in healthy volunteers at multiple dose levels and was well-tolerated by study participants. VIT-2763 is also being tested in people with another blood disorder called thalassemia.
To take part, you must
- Be 18 to 60 years of
- Have SCD, including HbS/S or HbS/βT0 genotype (but NOT HbS/βT+ genotype or HbSC disease). The study doctor can tell you what kind of SCD you have if you are not sure.
- Have had 1-10 vaso-occlusive crises within 12 months prior to study screening. These are also called ‘sickle cell pain crises’ or ‘VOC episodes’.
- Not have chronic liver disease or a history of liver Other criteria will also be reviewed to see if you can take part.
-The expected duration is max 16 weeks (up to 4 weeks screening period, 8 weeks of treatment and 4 weeks safety follow-up)
-The study involves 7 outpatient visits.
-Eligible participants may receive compensation for their participation in the study, plus reasonable travel expenses.
-24 participants will take part in the study
You can also Download a PDF of the Clinical Trial Leaflet Here which gives full information on the trial.
If you are interested in finding out more, or participating in the study then please contact your nearest Clinical Trial Location.
Clinical trial locations
-Barts Health NHS Trust – Please Contact: Tasnima Ferdousi Phone: 020 324 60261
-King´s College hospital NHS foundation Trust– Please Contact: Katia Mercone, Phone: 020 329 95772
-Homerton University Hospital NHS Foundation Trust – Please Contact: Jagrul Miah, Phone: 020 851 05117
-Royal Liverpool University Hospital – Please Contact: Samuel Badu, Phone: 015 170 63397
-Manchester University NHS Foundation Trust – Please contact: Charlene Hyde, email: NMH.Trials@mft.nhs.uk
-Imperial College healthcare NHS Trust – Please Contact: Camelia Vladescu, Phone: 020 331 31195